Showing 4421-4430 of 7638 results for "".
- Sente, Inc. Awarded European Patent for Active Ingredient in Proprietary Dermal Repair Creamhttps://practicaldermatology.com/news/20140619-sente_inc_awarded_european_patent_for_active_ingredient_in_proprietary_dermal_repair_cream/2459199/Sente has been granted the European Patent for use of a low molecular weight heparan sulfate (HS) for cosmetic products. HS is the most biologically active glycoprotein that is present in all layers of human skin and is the scientific base to Sente Inc's proprietary Dermal Repair Cream. Michael Yo…
- Valeant Commences Exchange Offer For Allerganhttps://practicaldermatology.com/news/20140618-valeant_commences_exchange_offer_for_allergan/2459200/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), taking its May 30th proposal directly to Allergan stockholders. Under the terms of the offer, Aller…
- Valeant Pharmaceuticals Receives FDA Clearance For Restylane Silkhttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_receives_fda_clearance_for_restylane_silk/2459205/The FDA issued marketing clearance for Valeant Pharmaceuticals International, Inc.'s Restylane Silk Injectable Gel with 0.3% Lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. Restylane Silk is a cry…
- TruInject Injector Training System Receives Approval of Its Patenthttps://practicaldermatology.com/news/20140613-truinject_injector_training_system_receives_approval_of_its_patent/2459207/One of the key patent applications of TruInject Medical Corporation has been allowed by the US Patent Office. The patent is expected to issue shortly. The patent is for a cosmetic and therapeutic injector training system and is one of many patents filed both domestically and internationally by Tru…
- New Data Demonstrate Efficacy of ClarityMD OTC Acne Systemhttps://practicaldermatology.com/news/20140611-new_data_demonstrate_efficacy_of_claritymd_otc_acne_system/2459210/Newly published data show the efficacy of Envy Medical's ClarityMD acne system. Results of a clinical study designed by Envy, demonstrate that ClarityMD is effective in quickly and gently clearing both inflammatory and non-inflammatory acne lesions. Findings appear in the June edition of the "Jou…
- San Francisco Dermatologist Elected to AMA Board of Trusteeshttps://practicaldermatology.com/news/20140611-san_francisco_dermatologist_elected_to_ama_board_of_trustees/2459211/Jack Resneck Jr., MD, a dermatologist from San Francisco, CA, was elected to the American Medical Association (AMA) Board of Trustees. "I am honored to be elected to the AMA Board of Trustees," said Resneck. "Our AMA has an influential role to play in convening medicine, exerting influence where i…
- Allergan Again Unanimously Rejects Valeant's Revised Unsolicited Proposalhttps://practicaldermatology.com/news/20140610-allergan_again_unanimously_rejects_valeants_revised_unsolicited_proposal/2459212/Allergan has once again rejected the revised unsolicited proposal from Valeant and Pershing Square Capital Management, setting the stage for a lengthy hostile takeover battle. Allergan announced Tuesday that its board of directors, after consulting with its independent financial and legal advisor…
- Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosishttps://practicaldermatology.com/news/20140609-valeant_pharmaceuticals_announces_fda_approval_of_jublia_for_the_treatment_of_onychomycosis/2459213/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazol…
- Allergan: Business As Usual Following New Valeant Offerhttps://practicaldermatology.com/news/20140606-allergan_business_as_usual_following_new_valeant_offer/2459215/At Allergan, executives say it is business as usual, even as the board reviews a hefty new offer from Valeant. Valeant last Friday increased its offer to Allergan by $14 per share, “subject to prompt good-faith discussions on a merger agreement.” The new bid values Allergan at about $180 a share an…
- Cosmetic Surgery Forum Unveils 2014 Agendahttps://practicaldermatology.com/news/20140606-cosmetic_surgery_forum_unveils_2014_agenda/2459216/The agenda for the 2014 Cosmetic Surgery Forum was recently unveiled. The meeting will take place from December 3 through December 6 at the Palazzo Casino and Resort in Las Vegas, NV. Under course director Joel Schlessinger, MD, this year's meeting will include sessions on cosmetic treatments for m…